Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Cardiome closes C$30 million primary and secondary common share offering

Reading Time 1 minute read Subscribe



Confidential Clients

On March 11, 2014, Cardiome Pharma Corp. (“Cardiome”) and CarCor Investment Holdings LLC (“CarCor”), the shareholder from which Cardiome purchased Correvio LLC, completed a prospectus offering of 1,500,000 common shares from treasury of Cardiome for gross proceeds of C$15 million and 1,500,000 common shares in a secondary offering from CarCor for gross proceeds of C$15 million, both at C$10.00 per common share, for aggregate gross proceeds of C$30 million. The offering was made on a bought deal basis through a syndicate of underwriters with Canaccord Genuity Corp., acting as sole bookrunner and co-lead underwriter, and Cormark Securities Inc., acting as co-lead underwriter. The underwriters were advised by a team of Fasken Martineau lawyers that included Rubin Rapuch, Brad Freelan, Jessica Catton, Aidan Hyde (Capital Markets) and Mark Penner (Intellectual Property).



    Receive email updates from our team